Nebido (Testosterone Undecanoate)

Testosterone undecanoate is an ester of testosterone that, after intramuscular injection, is slowly hydrolyzed to testosterone. The released testosterone binds to intracellular androgen receptors, influencing gene transcription that promotes anabolic processes, development of male secondary sexual characteristics, and maintenance of libido, muscle mass, and bone density.

The dosing regimen for Nebido is individualized; a qualified prescriber determines the appropriate dose and injection interval based on the patient’s serum testosterone levels, clinical response, and safety monitoring. Typical regimens involve an initial loading dose followed by maintenance injections, but exact amounts must be set by the treating physician.

Nebido is contraindicated for use in women who are pregnant or breastfeeding. Testosterone can cross the placenta and be present in breast milk, potentially causing virilization of a female fetus or adverse effects in a nursing infant. Therefore, it should only be prescribed to male patients unless otherwise directed by a specialist.

To request Nebido, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain handling where required—and assistance with import documentation.

Nebido offers a long‑acting intramuscular formulation that requires fewer injections (typically every 10‑14 weeks) compared with shorter‑acting testosterone esters that may need weekly or bi‑weekly dosing. This can improve patient adherence and maintain more stable serum testosterone levels, though individual response and safety profiles should be evaluated against alternatives such as testosterone gel or patches.

Nebido must be stored at 2‑8 °C in a refrigerator, protected from light. The vial should remain in its original packaging, should not be frozen, and must be handled gently to avoid agitation. Prior to administration, the product should be allowed to reach room temperature if required by the prescribing information.

Nebido is given as an intramuscular injection, usually into the gluteal muscle. The injection is performed by a qualified healthcare professional using aseptic technique. After administration, the site should be monitored for any immediate adverse reactions, and the patient should be scheduled for follow‑up visits to assess testosterone levels and clinical response.

The most serious risks include cardiovascular events such as myocardial infarction or stroke, liver toxicity, and the potential acceleration of pre‑existing prostate cancer. Additionally, severe allergic reactions and thromboembolic events can occur. Patients should be regularly monitored for signs of these complications, and therapy should be discontinued if serious adverse effects are identified.

Nebido is not recommended for individuals with known hypersensitivity to testosterone undecanoate or any excipients, for patients with active prostate or breast cancer, for those with severe untreated sleep apnea, uncontrolled heart failure, or significant cardiovascular disease. It is also contraindicated in women who are pregnant or lactating. Use should be avoided unless a specialist determines that benefits outweigh the risks.